Amneal Corp (AMRX) - מקדם חוב לטווח ארוך להון

Amneal Pharmaceuticals (AMRX) relies on a sustainable economic moat driven by its extensive portfolio of complex injectables and biosimilars. The market trend for long-term debt, visualized in monetary terms, is 79.92. The founding team is skillfully scaling the product pipeline while optimizing costs. The business demonstrates low dependence on market cycles, as the demand for affordable therapy increases during downturns.

Amneal Pharmaceuticals (AMRX) competitiveness in the generics segment depends on large-scale investments in production capacities to reduce unit costs. The long-term debt-to-equity ratio at 79.92, shown on the GURU.Markets chart, quantifies the balance between long-term loans and equity, allowing investors to assess financial stability and default risk when implementing capital-intensive expansion strategies.